60bc0507-0349-4154-9db4-8d93b3e8bdf5
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 64
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- HEDGEHOG_SIGNALING+0.390
- COAGULATION+0.370
- PANCREAS_BETA_CELLS+0.370
- ANGIOGENESIS+0.360
- INTERFERON_ALPHA_RESPONSE+0.360
- APICAL_JUNCTION+0.320
- MYOGENESIS+0.210
- UV_RESPONSE_DN+0.180
- PROTEIN_SECRETION+0.160
Top 10 suppressed
- E2F_TARGETS-0.520
- MYC_TARGETS_V1-0.460
- MYC_TARGETS_V2-0.450
- G2M_CHECKPOINT-0.400
- DNA_REPAIR-0.370
- CHOLESTEROL_HOMEOSTASIS-0.330
- MTORC1_SIGNALING-0.280
- ALLOGRAFT_REJECTION-0.260
- FATTY_ACID_METABOLISM-0.250
- OXIDATIVE_PHOSPHORYLATION-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-97-8547-01A-11R-2403-07 | — | cohortA1 | 0.837 |
| 2 | TCGA-CV-5444-01A-02R-1514-07 | — | — | 0.823 |
| 3 | 44eb0b78-9761-4131-b831-85e765a24e6b | — | — | 0.814 |
| 4 | TCGA-CN-5361-01A-01R-1436-07 | — | — | 0.810 |
| 5 | TCGA-IQ-A61J-01A-11R-A30B-07 | — | — | 0.804 |
| 6 | TCGA-QK-A8Z9-01B-11R-A39I-07 | — | — | 0.798 |
| 7 | TCGA-44-6147-01A-11R-1755-07 | — | cohortA1 | 0.793 |
| 8 | TCGA-CN-6016-01A-11R-1686-07 | — | — | 0.793 |
| 9 | 52a10f37-ee39-4805-908e-b9e35fa983e9 | — | — | 0.790 |
| 10 | TCGA-05-4405-01A-21R-1858-07 | — | cohortA1 | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.390 | Inavolisib | — uncovered |
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.160 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| COMPLEMENT | 0.110 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |